ESR1 and breast carcinoma: However, we did not observe any advantage of amcenestrant over letrozole, a finding consistent with interim data from the Phase 3 AMEERA-5 trial (amcenestrant versus letrozole, both in combination with palbociclib, as first-line treatment for advanced or metastatic ER+/HER2− breast cancer) [26].